DaTscan (I-123 Ioflupane) SPECT Imaging

A DaTscan is a SPECT study using ioflupane I-123 to image presynaptic dopamine transporters in the striatum, helping clinicians distinguish neurodegenerative parkinsonism from conditions such as essential tremor that do not involve dopaminergic neuron loss. Its diagnostic value depends on correct patient preparation, thyroid blocking, careful gamma-camera acquisition and QC, and a sound interpretation of striatal uptake patterns and semiquantitative indices.¹²³

Ioflupane I-123 (DaTscan) binds with high affinity to the dopamine transporter (DAT) on presynaptic nigrostriatal terminals. Because those terminals are lost in nigrostriatal degenerative disease, the scan provides a direct in-vivo marker of dopaminergic integrity that clinical examination alone cannot supply.²³ This guide walks through the radiopharmaceutical, the physics of I-123 imaging, the acquisition protocol, semiquantitative analysis, quality control, clinical impact, and the regulatory framework, and how DRPS supports DAT SPECT programs through PET/CT and nuclear medicine physics.

Introduction

The central clinical question DaTscan answers is whether a patient's parkinsonian features arise from loss of nigrostriatal dopaminergic terminals. Parkinsonian syndrome encompasses several neurodegenerative diseases — Parkinson disease (PD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB) — all of which feature presynaptic dopaminergic deficit. Essential tremor, drug-induced tremor, vascular parkinsonism, and psychogenic tremor do not. Their clinical overlap is the diagnostic dilemma, and their management differs substantially.²

An abnormal ioflupane I-123 SPECT scan indicates reduced striatal dopamine transporter density — that is, nigrostriatal degeneration — whereas a normal scan supports a non-degenerative cause such as essential tremor.² What the scan does not do is separate PD from the atypical degenerative syndromes; all of those produce an abnormal scan.³

This distinction has real consequences. In a multicenter study of patients with clinically uncertain parkinsonian syndromes, ioflupane SPECT changed the diagnosis in roughly half and altered clinical management in about 72% of patients.⁶ The remainder of this guide explains how to produce a study reliable enough to support those decisions.

Topic Explanation

The radiopharmaceutical and its target

Ioflupane I-123 is a cocaine analog that binds the presynaptic dopamine transporter, so the SPECT signal in the striatum is proportional to the density of intact dopaminergic terminals. Imaging is performed several hours after injection, when specific striatal binding is high relative to background.

The striatum has two functionally relevant parts on a DaT scan:

• Caudate nucleus — relatively preserved early in nigrostriatal degeneration.
• Putamen — typically affected first and most severely, especially the posterior putamen.

A normal study therefore shows two symmetric, comma- or crescent-shaped foci of intense uptake (caudate plus putamen bilaterally). Degeneration erodes the putaminal tail first, producing an asymmetric "period" or "full stop" appearance as uptake collapses toward the caudate.²³

Why iodine-123 and why thyroid blocking

I-123 is well suited to SPECT: it decays by electron capture with a principal gamma emission near 159 keV (emitted in roughly 83% of decays) and a physical half-life of about 13.2 hours, which matches the imaging time course and limits patient dose.⁷ However, the injection may contain up to about 6% free iodide. Free I-123 iodide is concentrated by the thyroid, where it could increase long-term neoplasia risk, so the prescribing information requires thyroid blocking with a stable iodine agent before injection.¹

A practical complication is that I-123 also emits a small fraction of higher-energy photons (around 529 keV and above). These can penetrate the septa of a low-energy collimator, adding a background "halo" of mispositioned counts that degrades contrast and can bias semiquantitative results — a key QC consideration discussed below and in our guide to gamma-camera collimator selection.³

Key Technical Principles

Decay and timing

The administered activity decays according to:

$$A(t)=A_0{e}^{-\lambda t},\lambda =\frac{\ln 2}{T_{1/2}}=\frac{0.693}{13.2\text{h}}\approx 0.0525{\text{h}}^{-1}$$

At a 4-hour imaging start, the remaining fraction of injected activity is:

$$\frac{A(4)}{A_0}=e^{-0.0525\times 4}\approx 0.81$$

So about 81% of the injected I-123 remains at the start of a 4-hour acquisition, which — combined with favorable striatum-to-background kinetics in the 3-to-6-hour window — is why the prescribing information specifies that imaging window.¹⁷

Acquisition parameters

The single most important operational principle is consistency: the same camera, collimator, energy window, orbit, matrix, reconstruction, and filter should be used every time if semiquantitative analysis or normal-database comparison is performed, because the striatal binding ratio is sensitive to all of them.³⁴

Semiquantitative analysis: the striatal binding ratio

Visual interpretation by an experienced reader is the primary method, but semiquantification adds reproducibility. The striatal binding ratio (SBR), or specific binding ratio, compares specific striatal uptake to a non-specific reference region (commonly occipital cortex):

$$\text{SBR}=\frac{C_{\text{striatum}}-C_{\text{ref}}}{C_{\text{ref}}}$$

where $C_{\text{striatum}}$ is the mean counts per voxel in the striatal region of interest and $C_{\text{ref}}$ is the mean counts per voxel in the reference region.

For a worked example, suppose the striatal ROI returns a mean of 300 counts/voxel and the occipital reference returns 100 counts/voxel:

$$\text{SBR}=\frac{300-100}{100}=2.0$$

That value is then compared against an age-matched normal database, because DAT density declines with normal aging by several percent per decade. A standalone SBR has little meaning without that reference and without consistent acquisition and processing; this is why semiquantification supplements, rather than replaces, expert visual reading.³⁴ The same quantitative discipline underlies other count-based nuclear medicine measurements, as in our guide to thyroid uptake measurement.

Interpretation patterns

The scan localizes the deficit, not the disease entity: an abnormal scan supports nigrostriatal degeneration but does not, on its own, distinguish PD from PSP, MSA, or CBD.²³

Clinical Impact

DaTscan changes management precisely because it resolves diagnostic uncertainty that examination cannot. Reported diagnostic performance is strong: across multiple multicenter studies, sensitivity and specificity for detecting striatal dopaminergic deficit were high and improved as the clinical reference diagnosis matured with longer follow-up, with between-reader agreement frequently in the "almost perfect" range.⁵

Concretely, the evidence supports several clinical uses:

• Separating essential tremor from early degenerative parkinsonism, where the treatments and prognoses diverge.
• Clarifying clinically uncertain parkinsonian syndromes, where imaging changed the working diagnosis in roughly half of patients and altered management in about 72% in one multicenter cohort.⁶
• Supporting the workup of suspected dementia with Lewy bodies, where a dopaminergic deficit favors DLB over Alzheimer disease.⁵

Because these are decisions about long-term therapy, a technically reliable scan matters. A poorly peaked camera, an inappropriate collimator, septal penetration, non-uniformity, or center-of-rotation error can shift uptake patterns and SBR values enough to influence interpretation — which is why the QC program is inseparable from the clinical value.

Practical Optimization Tips

1. Confirm and document thyroid blocking

Administer a stable iodine agent before injection per the prescribing information and the facility protocol, and document it. This is a patient-safety step, not an optional courtesy.¹

2. Screen for interfering medications

Several drugs affect DAT binding or compete at the transporter. Review the patient's medications against the prescribing information and guideline contraindications, and coordinate any clinically appropriate holds with the referring physician before scheduling.¹³

3. Lock down acquisition and processing

Use the same camera, collimator, energy window, orbit, matrix, reconstruction algorithm, and filters every time when semiquantitative analysis or a normal database is used. Drift in any of these undermines SBR comparability.³⁴

4. Manage I-123 high-energy photons

Recognize that the higher-energy I-123 photons can penetrate LEHR collimator septa. Follow the collimator recommendation in your protocol and validate the chosen configuration; septal penetration degrades contrast and biases quantification.³

5. Run and trend gamma-camera QC

• Energy peaking on the 159 keV photopeak each imaging day.
• Uniformity correction and routine flood checks.
• Center-of-rotation (COR) verification on the schedule, since COR error blurs the small striatal structures.
• Resolution/SPECT phantom checks per the facility program.

These are the same fundamentals covered in our guide to SPECT/CT quality control; for DAT SPECT they are decisive because the target structures are small and high-contrast.

Common pitfalls to avoid

• Skipping or under-documenting thyroid block.
• Changing acquisition or processing between baseline and follow-up studies.
• Reading SBR without an age-matched normal database.
• Over-reading a normal-variant or a technically degraded scan as abnormal.
• Expecting the scan to name the specific degenerative syndrome.

Regulatory Considerations

Ioflupane I-123 is byproduct material, so its medical use is governed by NRC 10 CFR Part 35 (or the equivalent Agreement State program), with radiation protection standards under 10 CFR Part 20. The radiopharmaceutical must be administered under an authorized user, and the facility's license must authorize the relevant use.⁸⁹

Key regulatory and standards anchors:

• FDA prescribing information — defines the recommended administered activity (111–185 MBq), the 3-to-6-hour imaging window, the 159 keV ±10% photopeak, the ≥120-view acquisition, and the mandatory thyroid-blocking step.¹
• 10 CFR Part 35 — medical use of byproduct material, including authorized-user requirements and the radiation safety program for administration.⁸
• 10 CFR Part 20 — occupational and public dose standards that frame handling, surveys, and waste for the I-123 dose.⁹
• Professional guidelines — the ACR-ACNM Practice Parameter, the EANM/SNMMI procedure standard, and the SNM practice guideline define performance, interpretation, and reporting expectations.²³⁴

Jurisdiction matters for the materials license: of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use of byproduct material under their own programs, while Washington DC and Delaware are regulated directly by the NRC. Patients receiving diagnostic I-123 ioflupane doses are routinely released without restriction, but the program must still meet authorized-use, survey, and documentation requirements. DRPS supports this through radioactive material license support and nuclear medicine physics services.

Frequently Asked Questions (FAQs)

What is a DaTscan?

DaTscan is the brand name for ioflupane I-123 injection, a radiopharmaceutical that binds to presynaptic dopamine transporters (DAT) in the striatum. Using SPECT brain imaging, it shows the density and distribution of those transporters, which helps distinguish neurodegenerative parkinsonian syndromes from conditions such as essential tremor that do not involve loss of dopaminergic neurons.

What does a DaTscan actually measure?

It measures the integrity of presynaptic nigrostriatal dopaminergic terminals by imaging dopamine transporter density in the caudate and putamen. A normal study shows symmetric, comma- or crescent-shaped uptake in both striata; an abnormal study shows reduced, asymmetric uptake, typically beginning in the putamen, indicating nigrostriatal degeneration.

Why is thyroid blocking required before a DaTscan?

Ioflupane I-123 injection may contain a small amount of free iodide (iodine-123), up to about 6 percent, which the thyroid would otherwise concentrate and which could raise the long-term risk of thyroid neoplasia. The thyroid is therefore blocked with a stable iodine agent before injection, per the prescribing information, to reduce thyroid uptake of free iodine-123.

What is the recommended administered activity and imaging time?

The FDA prescribing information recommends an administered activity of 111 to 185 MBq (3 to 5 mCi) of ioflupane I-123, with SPECT imaging beginning between 3 and 6 hours after injection. Images are acquired with the camera set to a 159 keV photopeak using a plus or minus 10 percent energy window.

What is a striatal binding ratio?

A striatal binding ratio (SBR), or specific binding ratio, is a semiquantitative index comparing counts in a striatal region of interest to counts in a reference region with little specific binding, such as the occipital cortex. It supplements, but does not replace, expert visual interpretation, and is most useful when compared against an age-matched normal database.

Can a DaTscan distinguish Parkinson disease from atypical parkinsonism?

Not by itself. A DaTscan reliably separates nigrostriatal degenerative parkinsonism (including Parkinson disease, progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration) from non-degenerative causes such as essential tremor or drug-induced tremor. It does not reliably differentiate Parkinson disease from the atypical degenerative parkinsonian syndromes.

What quality control supports a reliable DaTscan?

Reliable DAT SPECT depends on routine gamma-camera QC, including energy-peak calibration, uniformity correction, center-of-rotation verification, and attention to collimator selection and septal penetration from the higher-energy photons of I-123. Consistent acquisition, reconstruction, and processing are essential when semiquantitative analysis is used.

Key Takeaways

• DaTscan images dopamine transporters, providing an in-vivo marker of nigrostriatal integrity that separates degenerative parkinsonism from non-degenerative causes.²
• It localizes a deficit, not a disease; an abnormal scan does not distinguish PD from PSP, MSA, or CBD.³
• Thyroid blocking is mandatory because the injection can contain up to ~6% free I-123 iodide.¹
• Protocol matters: 111–185 MBq, 3–6 hour imaging, 159 keV ±10% window, ≥120 views.¹
• Semiquantitative SBR supplements visual reading and is only meaningful with consistent technique and an age-matched normal database.³⁴
• QC is inseparable from clinical value: energy peaking, uniformity, COR, and collimator/septal-penetration management protect both the image and the SBR.

Conclusion

DaTscan SPECT with ioflupane I-123 is a powerful adjunct for resolving diagnostic uncertainty in movement disorders and suspected Lewy body dementia. Its reliability is engineered, not assumed: correct thyroid blocking, medication screening, a tightly controlled acquisition and processing chain, disciplined gamma-camera QC, and interpretation that respects what the scan can and cannot tell you. When those elements are in place, the study delivers the diagnostic confidence that changes management for a substantial share of patients.⁵⁶

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine programs performing DAT SPECT with gamma-camera acceptance testing and annual surveys, uniformity and center-of-rotation evaluation, energy-peak and collimator verification, SPECT phantom analysis, protocol and semiquantification review, and radiation safety and licensing support — all delivered by board-certified medical physicists.

DRPS serves facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware, through PET/CT and nuclear medicine physics and medical physicist consulting.

Related Resources

• Gamma-camera collimator selection
• SPECT/CT quality control
• Cardiac SPECT MPI quality control
• Thyroid uptake measurement
• PET/CT and nuclear medicine physics
• Medical physicist consulting

References

1. GE Healthcare. DaTscan (Ioflupane I 123 Injection) Prescribing Information. U.S. Food and Drug Administration; 2022. accessdata.fda.gov
2. Subramaniam RM, Frey KA, Hunt CH, et al. ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) SPECT Imaging for Movement Disorders. Clin Nucl Med. 2017;42(11):847-852. doi:10.1097/RLU.0000000000001815. doi.org
3. Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47(8):1885-1912. doi:10.1007/s00259-020-04817-8. doi.org
4. Djang DSW, Janssen MJR, Bohnen N, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154-163. doi:10.2967/jnumed.111.100784. doi.org
5. Seibyl JP, Kupsch A, Booij J, et al. Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. J Nucl Med. 2014;55(8):1288-1296. doi:10.2967/jnumed.114.140228. doi.org
6. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19(10):1175-1182. doi:10.1002/mds.20112. doi.org
7. National Nuclear Data Center, Brookhaven National Laboratory. NuDat: Iodine-123 decay data (159 keV gamma; T_1/2 ≈ 13.2 h). nndc.bnl.gov
8. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
9. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. nrc.gov